Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in...
20 insider purchases on record · latest filing 2025-01-13.
Insiders have also filed 130 sale transactions at OLMA.